3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors

A method of inhibiting KMO activity comprising administering an effective amount of a compound of Formula (I):

• wherein:
• X is a bond and Rt is H, -halo or CN;
• X is CH2 and Rt is —H or —C1-3alkyl;
• X is —O— and R1 is —C1-4alkyl, —(CH2)mCF3, —CHR2CH2OMe, —(CH2)nC3-4cycloalkyl, —(CH2)noxetane, -benzyl or —CHR2heteroaryl;
• wherein:
• the heteroaryl as defined in —CHR2 heteroaryl is additionally substituted by halo, methyl, ethyl or O;
• m=1 or 2;
• n=0 or 1;
• R2=—H, -methyl or -ethyl;
• R3=H or -methyl;
• or
• a pharmaceutically acceptable salt thereof;
• to a subject in need thereof, wherein diseases treatable by such inhibition include acute pancreatitis, Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amyotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.